Clinical Trials Logo

Leukemia, Lymphoid clinical trials

View clinical trials related to Leukemia, Lymphoid.

Filter by:

NCT ID: NCT02028039 Withdrawn - Leukemia Clinical Trials

IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

Start date: December 2013
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if IPI-145 can help to control the disease in patients with ALL. The safety of the study drug will also be studied.

NCT ID: NCT02020109 Withdrawn - Clinical trials for Leukemia, Chronic Lymphatic

Evaluation of Splenic Irradiation in Chronic Lymphatic Leukemia

Start date: September 2013
Phase:
Study type: Observational

Retrospective evaluation on the effect of splenic irradiation on clinical and hematological response and toxicity in patients with chronic lymphatic leukaemia (CLL).

NCT ID: NCT02015208 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia

Start date: April 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine if Ruxolitinib, an inhibitor of cytokine-signaling, is effective in the treatment of patients with Chronic Lymphocytic Leukemia for whom conventional chemotherapy is either too toxic or ineffective.

NCT ID: NCT02013817 Completed - Clinical trials for Lymphocytic Leukemia, Chronic

CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy

Start date: October 2005
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of intense combination treatment including MabThera/Rituxan (rituximab), followed by MabThera/Rituxan maintenance therapy in patients with B-cell CLL who are naive to chemotherapy. The anticipated time on study treatment is 2.5 years.

NCT ID: NCT02013167 Terminated - Clinical trials for Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Start date: January 3, 2014
Phase: Phase 3
Study type: Interventional

The primary objective was to evaluate the effect of blinatumomab on overall survival when compared to standard of care (SOC) chemotherapy.

NCT ID: NCT02011022 Completed - Clinical trials for Methotrexate Adverse Reaction

Pharmacokinetic Analysis of High Dose Methotrexate in Pediatric Lymphoblastic Malignancies

HDMTX
Start date: May 2009
Phase: N/A
Study type: Interventional

* The pharmacokinetics of MTX were assessed with regards to the relevance of several different patient specific factors in 291 pediatric patients, who were administered with high dose of MTX. Population pharmacokinetics of MTX analysis was performed by using nonlinear mixed effects modeling.

NCT ID: NCT02010931 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Leukemia Patients

Start date: September 2013
Phase:
Study type: Observational

A retrospective analysis of historical data looking at relapse free survival and overall survival rates in adult philadelphia negative B-pre-cursor acute lymphoblastic leukemia patients.

NCT ID: NCT02007863 Completed - Leukemia Clinical Trials

Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia

Start date: August 2008
Phase: N/A
Study type: Interventional

Unrelated Cord Blood (UCB) transplant in children is a viable stem cell transplant modality for patients with leukemia and myelodysplasia. UCB is now considered "Standard Of Care" in cases where a suitable living bone marrow donor is not available. The survival of UCB is similar to Matched Unrelated Marrow Transplant. This study is considered "Research" since UCB is not a licensed product and requires investigational new drug (IND). THERE ARE NO SPECIFIC RESEARCH QUESTIONS IN THIS PROTOCOL. This protocol merely provides UCB as a stem cell treatment modality to pediatric patients who may require it after a conditioning regimen that excludes Total Body Irradiation.

NCT ID: NCT02007811 Recruiting - Multiple Myeloma Clinical Trials

Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination

B-cell therapy
Start date: November 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The reconstitution of a functioning immune system after allogeneic stem cell transplantation takes months to years. Particularly memory B-lymphocytes reconstitute poorly with the current conditioning regimes. During the period of intense immune suppression the patients are extremely susceptible to bacterial, fungal and, most importantly, viral infections.The adoptive transfer of B-lymphocytes from the stem-cell donor might significantly enhance humoral immunity for the patient. Aim of the study is to evaluate a new cellular therapy with B-lymphocytes regarding safety. A booster vaccination after B-lymphocyte transfer will evaluate the functionality of the transferred B-lymphocytes in the patient.

NCT ID: NCT02007044 Active, not recruiting - Clinical trials for Recurrent Small Lymphocytic Lymphoma

Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Start date: December 6, 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies ibrutinib with or without rituximab in treating patients with chronic lymphocytic leukemia that has come back after treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as rituximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether ibrutinib is more effective with or without rituximab in treating chronic lymphocytic leukemia.